Posted by Michael Wonder on 07 Sep 2018
FDA approves Grifols new GamaSTAN (immunoglobulin [human]) to treat patients exposed to hepatitis A and measles
4 September 2018 - New formulation is manufactured using Grifols' sophisticated caprylate chromatography process according to the highest quality and safety standards.
Grifols announced that the U.S. FDA has approved a new formulation of its GamaSTAN immune globulin (human) for hepatitis A virus (HAV) and measles post-exposure prophylaxis. GamaSTAN is now available to health care providers across the country.
GamaSTAN is the only immune globulin product on the U.S. market approved for immediate protection against HAV and measles. The FDA approval is an important R&D milestone for Grifols as a global leader in post-exposure prophylaxis (the treatment of a person after exposure to a virus) and immune globulin products for patients.
